Novo Nordisk A/S
Stocks making the biggest moves midday: Spotify, Regeneron, Hims & Hers, Pfizer and more
Check out the companies making headlines in midday trading: Spotify — Shares of the music streaming company lost 3.8% on the back of disappointing results. Spotify reported first-quarter operating income of 509 million euros, while analysts polled by FactSet expected 519.9 million euros. Spotify’s revenue of 4.2 billion euros was in line with estimates, while […]
Read More
Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 30%
The “Wegovy” brand slimming syringe is sold in the Achat pharmacy in Mitte. The “Wegovy” slimming syringe has been available in Germany for a year. Jens Kalaene | Picture Alliance | Getty Images Novo Nordisk on Tuesday said it will offer its weight loss drug Wegovy through telehealth providers Hims & Hers Health, Ro and […]
Read More
Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic
Flags with the logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy are pictures while the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images Novo Nordisk scored a huge legal victory that […]
Read More
Healthy Returns: Trump seeks to change Medicare drug price negotiations in a win for pharma
U.S. President Donald Trump speaks to the media during the annual White House Easter Egg Roll, on the South Lawn of the White House in Washington, D.C., U.S., April 21, 2025. Leah Millis | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to […]
Read More
5 European stocks to watch this earnings season as Trump’s tariffs hit
Investors are entering 2025’s first-quarter earnings season with a huge cloud of uncertainty hanging over them — thanks primarily to U.S. President Donald Trump’s tariffs. The scale of duties announced in April, along with the volatility injected by subsequent updates and reversals in policy, have so far exceeded even the most bearish forecasts. Negotiators from […]
Read More
Eli Lilly shares surge on new obesity pill data. What it means for the stock from here
Eli Lilly is tightening its grip on the lucrative weight-loss market as it moves into a new, more convenient phase that promises to broaden the appeal of its breakthrough drugs. The news Club name Lilly said its daily obesity pill was successful in a late-stage trial for Type 2 diabetes — sending shares soaring more […]
Read More
Eli Lilly’s weight loss pill succeeds in first late-stage trial on diabetes patients
Eli Lilly on Thursday said its daily obesity pill met the company’s goals in the first of several late-stage trials, helping Type 2 diabetes patients lower their blood sugar and body weight and showing safety on par with popular injections on the market. The trial results are among the pharmaceutical industry’s most closely watched studies […]
Read More
LVMH plunge puts spot as world’s top luxury stock at risk after sales miss
Louis Vuitton store window display in Mitsukoshi department store in Tokyo, Japan, on Friday, April 4, 2025. Bloomberg | Getty Images Shares of LVMH plunged as much as 8% on Tuesday morning, at one point losing its position as world’s largest luxury firm to rival Hermès after an unexpected decline in first-quarter sales. LVMH reported […]
Read More
CNBC Daily Open: Consumers are worried over the economy. The White House insists it’ll be fine
People shop at a grocery store in Manhattan on April 01, 2025, in New York City. Spencer Platt | Getty Images A day without major tariff developments from U.S. President Donald Trump’s administration is, for markets, a day of cautious optimism (or at least what passes as “optimism” in such unusual times). There was breathing […]
Read More
Pfizer scraps daily weight loss pill after liver injury in one patient
Nikos Pekiaridis | Lightrocket | Getty Images Pfizer on Monday said it would end development of its experimental daily weight loss pill after a patient experienced a liver injury that was potentially caused by the drug in a trial. The patient did not experience any liver-related symptoms or side effects, a Pfizer spokesperson said in […]
Read More